Please enable JavaScript to continue using this application.

Compare $RLAY vs $TVTX | Chartloom

Compare

$RLAY vs $TVTX

Relay Therapeutics Inc · Travere Therapeutics Inc

RLAY

Relay Therapeutics Inc

TVTX

Travere Therapeutics Inc

Compare $RLAY vs $TVTX

Comparing Relay Therapeutics Inc and Travere Therapeutics Inc

RLAYRelay Therapeutics Inc

TVTXTravere Therapeutics Inc

RLAYRelay Therapeutics Inc

Market cap

$3.85B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

610.65x

Rev growth (TTM)

23.9%

YTD performance

118.6%

52W performance

192.6%

FCF yield

-5.5%

TVTXTravere Therapeutics Inc

Market cap

$4.85B

P/E (TTM)

—

Forward P/E (NTM)

30.06x

Forward P/S (NTM)

5.04x

Rev growth (TTM)

77.1%

YTD performance

31.9%

52W performance

99.0%

FCF yield

0.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

RLAY

TVTX

Detailed metrics comparison

RLAY

Relay Therapeutics Inc

TVTX

Travere Therapeutics Inc

Market Cap

RLAY$3.85B

TVTX$4.85B

Enterprise Value

RLAY$3.73B

TVTX$5.33B

Price

RLAY$17.88

TVTX$52.13

P/E Ratio

RLAYN/A

TVTXN/A

P/S Ratio

RLAY372.39x

TVTX8.20x

EV/Sales

RLAY360.68x

TVTX9.02x

EV/EBITDA

RLAY0.00x

TVTX216.50x

P/B Ratio

RLAY4.67x

TVTX218.84x

P/FCF Ratio

RLAYN/A

TVTX314.77x

EV/FCF

RLAY-17.59x

TVTX346.27x

PEG Ratio

RLAYN/A

TVTXN/A

Forward P/E (NTM)

RLAYN/A

TVTX30.06x

Forward P/S (NTM)

RLAY610.65x

TVTX5.04x

Revenue (TTM)

RLAY$10M

TVTX$591M

Revenue Growth (YoY)

RLAY23.9%

TVTX77.1%

Forward Rev Growth

RLAY64.1%

TVTX49.4%

Gross Margin (TTM)

RLAY0.0%

TVTX98.6%

Operating Margin (TTM)

RLAY0.0%

TVTX0.0%

EBITDA Margin (TTM)

RLAY-2978.0%

TVTX3.9%

Net Margin (TTM)

RLAY-2763.6%

TVTX-7.4%

FCF Margin (TTM)

RLAY-2050.3%

TVTX2.6%

Net Income (TTM)

RLAY$-286M

TVTX$-43M

FCF (TTM)

RLAY$-212M

TVTX$15M

EPS (TTM)

RLAY-$1.41

TVTX-$0.46

ROE (TTM)

RLAY-4227.0%

TVTX-5579.0%

ROA (TTM)

RLAY-3867.0%

TVTX-696.0%

ROIC (TTM)

RLAY-4227.0%

TVTX-940.0%

Cash

RLAY$121M

TVTX$118M

Debt

RLAY$0

TVTX$603M

Net Cash/Debt

RLAY$121M

TVTX$-485M

Current Ratio (TTM)

RLAY18.27x

TVTX4.05x

Quick Ratio (TTM)

RLAY18.10x

TVTX3.75x

Debt/Equity (TTM)

RLAY0.00x

TVTX24.58x

Debt/Assets (TTM)

RLAY0.0%

TVTX0.0%

Interest Coverage (TTM)

RLAYN/A

TVTXN/A

Net Debt/EBITDA (TTM)

RLAY0.00x

TVTX0.00x

Beta

RLAY1.71

TVTX1.08

52W Performance

RLAY192.6%

TVTX99.0%

YTD Performance

RLAY118.6%

TVTX31.9%

% from 52W High

RLAY-15.9%

TVTX-24.2%

% from 52W Low

RLAY205.6%

TVTX130.7%

Asset Turnover (TTM)

RLAY0.01x

TVTX0.95x

FCF Yield (TTM)

RLAY-5.5%

TVTX0.3%

Earnings Yield (TTM)

RLAY-7.4%

TVTX-0.9%

Dividend Yield (TTM)

RLAYN/A

TVTXN/A

Rule of 40

RLAY-2,026.4

TVTX79.7

EV/GP/RG

RLAYN/A

TVTX0.14

Ticker research

View RLAY research View TVTX research

Metric	RLAY Relay Therapeutics Inc	TVTX Travere Therapeutics Inc
Market & Valuation
Market Cap	$3.85B	$4.85B
Enterprise Value	$3.73B	$5.33B
Price	$17.88	$52.13
P/E Ratio	N/A	N/A
P/S Ratio	372.39x	8.20x
EV/Sales	360.68x	9.02x
EV/EBITDA	0.00x	216.50x
P/B Ratio	4.67x	218.84x
P/FCF Ratio	N/A	314.77x
EV/FCF	-17.59x	346.27x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	30.06x
Forward P/S (NTM)	610.65x	5.04x
Revenue & Growth
Revenue (TTM)	$10M	$591M
Revenue Growth (YoY)	23.9%	77.1%
Forward Rev Growth	64.1%	49.4%
Profitability
Gross Margin (TTM)	0.0%	98.6%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-2978.0%	3.9%
Net Margin (TTM)	-2763.6%	-7.4%
FCF Margin (TTM)	-2050.3%	2.6%
Net Income (TTM)	$-286M	$-43M
FCF (TTM)	$-212M	$15M
EPS (TTM)	-$1.41	-$0.46
ROE (TTM)	-4227.0%	-5579.0%
ROA (TTM)	-3867.0%	-696.0%
ROIC (TTM)	-4227.0%	-940.0%
Financial Health
Cash	$121M	$118M
Debt	$0	$603M
Net Cash/Debt	$121M	$-485M
Current Ratio (TTM)	18.27x	4.05x
Quick Ratio (TTM)	18.10x	3.75x
Debt/Equity (TTM)	0.00x	24.58x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.71	1.08
52W Performance	192.6%	99.0%
YTD Performance	118.6%	31.9%
% from 52W High	-15.9%	-24.2%
% from 52W Low	205.6%	130.7%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.95x
FCF Yield (TTM)	-5.5%	0.3%
Earnings Yield (TTM)	-7.4%	-0.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-2,026.4	79.7
EV/GP/RG	N/A	0.14
Ticker research	View RLAY research	View TVTX research

Valuation

P/S Ratio

TVTX

8.20x

RLAY

372.39x

EV/FCF

RLAY

-17.59x

TVTX

346.27x

Growth & revenue

Revenue Growth TTM

TVTX

77.1%

RLAY

23.9%

Forward Revenue Growth

RLAY

64.1%

TVTX

49.4%

Profitability & performance

Gross Margin

TVTX

98.6%

RLAY

0.0%

ROE

RLAY

-4227.0%

TVTX

-5579.0%

FCF Yield %

TVTX

0.3%

RLAY

-5.5%

52-Week Performance

RLAY

192.6%

TVTX

99.0%

Detailed metrics comparison

RLAY

Relay Therapeutics Inc

TVTX

Travere Therapeutics Inc

Market Cap

RLAY$3.85B

TVTX$4.85B

Enterprise Value

RLAY$3.73B

TVTX$5.33B

Price

RLAY$17.88

TVTX$52.13

P/E Ratio

RLAYN/A

TVTXN/A

P/S Ratio

RLAY372.39x

TVTX8.20x

EV/Sales

RLAY360.68x

TVTX9.02x

EV/EBITDA

RLAY0.00x

TVTX216.50x

P/B Ratio

RLAY4.67x

TVTX218.84x

P/FCF Ratio

RLAYN/A

TVTX314.77x

EV/FCF

RLAY-17.59x

TVTX346.27x

PEG Ratio

RLAYN/A

TVTXN/A

Forward P/E (NTM)

RLAYN/A

TVTX30.06x

Forward P/S (NTM)

RLAY610.65x

TVTX5.04x

Revenue (TTM)

RLAY$10M

TVTX$591M

Revenue Growth (YoY)

RLAY23.9%

TVTX77.1%

Forward Rev Growth

RLAY64.1%

TVTX49.4%

Gross Margin (TTM)

RLAY0.0%

TVTX98.6%

Operating Margin (TTM)

RLAY0.0%

TVTX0.0%

EBITDA Margin (TTM)

RLAY-2978.0%

TVTX3.9%

Net Margin (TTM)

RLAY-2763.6%

TVTX-7.4%

FCF Margin (TTM)

RLAY-2050.3%

TVTX2.6%

Net Income (TTM)

RLAY$-286M

TVTX$-43M

FCF (TTM)

RLAY$-212M

TVTX$15M

EPS (TTM)

RLAY-$1.41

TVTX-$0.46

ROE (TTM)

RLAY-4227.0%

TVTX-5579.0%

ROA (TTM)

RLAY-3867.0%

TVTX-696.0%

ROIC (TTM)

RLAY-4227.0%

TVTX-940.0%

Cash

RLAY$121M

TVTX$118M

Debt

RLAY$0

TVTX$603M

Net Cash/Debt

RLAY$121M

TVTX$-485M

Current Ratio (TTM)

RLAY18.27x

TVTX4.05x

Quick Ratio (TTM)

RLAY18.10x

TVTX3.75x

Debt/Equity (TTM)

RLAY0.00x

TVTX24.58x

Debt/Assets (TTM)

RLAY0.0%

TVTX0.0%

Interest Coverage (TTM)

RLAYN/A

TVTXN/A

Net Debt/EBITDA (TTM)

RLAY0.00x

TVTX0.00x

Beta

RLAY1.71

TVTX1.08

52W Performance

RLAY192.6%

TVTX99.0%

YTD Performance

RLAY118.6%

TVTX31.9%

% from 52W High

RLAY-15.9%

TVTX-24.2%

% from 52W Low

RLAY205.6%

TVTX130.7%

Asset Turnover (TTM)

RLAY0.01x

TVTX0.95x

FCF Yield (TTM)

RLAY-5.5%

TVTX0.3%

Earnings Yield (TTM)

RLAY-7.4%

TVTX-0.9%

Dividend Yield (TTM)

RLAYN/A

TVTXN/A

Rule of 40

RLAY-2,026.4

TVTX79.7

EV/GP/RG

RLAYN/A

TVTX0.14

Ticker research

View RLAY research View TVTX research

Metric	RLAY Relay Therapeutics Inc	TVTX Travere Therapeutics Inc
Market & Valuation
Market Cap	$3.85B	$4.85B
Enterprise Value	$3.73B	$5.33B
Price	$17.88	$52.13
P/E Ratio	N/A	N/A
P/S Ratio	372.39x	8.20x
EV/Sales	360.68x	9.02x
EV/EBITDA	0.00x	216.50x
P/B Ratio	4.67x	218.84x
P/FCF Ratio	N/A	314.77x
EV/FCF	-17.59x	346.27x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	30.06x
Forward P/S (NTM)	610.65x	5.04x
Revenue & Growth
Revenue (TTM)	$10M	$591M
Revenue Growth (YoY)	23.9%	77.1%
Forward Rev Growth	64.1%	49.4%
Profitability
Gross Margin (TTM)	0.0%	98.6%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-2978.0%	3.9%
Net Margin (TTM)	-2763.6%	-7.4%
FCF Margin (TTM)	-2050.3%	2.6%
Net Income (TTM)	$-286M	$-43M
FCF (TTM)	$-212M	$15M
EPS (TTM)	-$1.41	-$0.46
ROE (TTM)	-4227.0%	-5579.0%
ROA (TTM)	-3867.0%	-696.0%
ROIC (TTM)	-4227.0%	-940.0%
Financial Health
Cash	$121M	$118M
Debt	$0	$603M
Net Cash/Debt	$121M	$-485M
Current Ratio (TTM)	18.27x	4.05x
Quick Ratio (TTM)	18.10x	3.75x
Debt/Equity (TTM)	0.00x	24.58x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.71	1.08
52W Performance	192.6%	99.0%
YTD Performance	118.6%	31.9%
% from 52W High	-15.9%	-24.2%
% from 52W Low	205.6%	130.7%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.95x
FCF Yield (TTM)	-5.5%	0.3%
Earnings Yield (TTM)	-7.4%	-0.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-2,026.4	79.7
EV/GP/RG	N/A	0.14
Ticker research	View RLAY research	View TVTX research